These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 24283303)

  • 1. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis.
    Lencioni R; Kudo M; Ye SL; Bronowicki JP; Chen XP; Dagher L; Furuse J; Geschwind JF; de Guevara LL; Papandreou C; Takayama T; Yoon SK; Nakajima K; Lehr R; Heldner S; Sanyal AJ
    Int J Clin Pract; 2014 May; 68(5):609-17. PubMed ID: 24283303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON.
    Kudo M; Ikeda M; Takayama T; Numata K; Izumi N; Furuse J; Okusaka T; Kadoya M; Yamashita S; Ito Y; Kokudo N
    J Gastroenterol; 2016 Dec; 51(12):1150-1160. PubMed ID: 27106231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study.
    Ye SL; Chen X; Yang J; Bie P; Zhang S; Liu F; Liu L; Zhou J; Dou K; Hao C; Shao G; Xia Q; Chen Y; Yang J; Deng X; Liu Y; Yuan Y; Fu Z; Nakajima K; Yip CS; Lu Z
    Oncotarget; 2016 Feb; 7(6):6639-48. PubMed ID: 26735891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
    Turnes J; Díaz R; Hernandez-Guerra M; Gómez M; Castells L; Bustamante J; Espinosa MD; Fernández-Castroagudín J; Serrano T; Rendón P; Andrade R; Salgado M; Arenas J; Vergara M; Sala M; Polo BA; Granizo IM; Gonzálvez ML; Viudez A
    Gastroenterol Hepatol; 2015 Apr; 38(4):263-73. PubMed ID: 25583146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study.
    Marrero JA; Kudo M; Venook AP; Ye SL; Bronowicki JP; Chen XP; Dagher L; Furuse J; Geschwind JH; de Guevara LL; Papandreou C; Takayama T; Sanyal AJ; Yoon SK; Nakajima K; Lehr R; Heldner S; Lencioni R
    J Hepatol; 2016 Dec; 65(6):1140-1147. PubMed ID: 27469901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study.
    Kaneko S; Ikeda K; Matsuzaki Y; Furuse J; Minami H; Okayama Y; Sunaya T; Ito Y; Inuyama L; Okita K
    J Gastroenterol; 2016 Oct; 51(10):1011-21. PubMed ID: 26931117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study.
    Ye SL; Yang J; Bie P; Zhang S; Chen X; Liu F; Liu L; Zhou J; Dou K; Hao C; Shao G; Xia Q; Chen Y; Yang J; Deng X; Liu Y; Yuan Y; Fu Z; Nakajima K; Lv Z
    BMC Cancer; 2018 Mar; 18(1):247. PubMed ID: 29499662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data.
    Kim DY; Kim HJ; Han KH; Han SY; Heo J; Woo HY; Um SH; Kim YH; Kweon YO; Lim HY; Yoon JH; Lee WS; Lee BS; Lee HC; Ryoo BY; Yoon SK
    Cancer Res Treat; 2016 Oct; 48(4):1243-1252. PubMed ID: 26910470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study.
    Lencioni R; Kudo M; Ye SL; Bronowicki JP; Chen XP; Dagher L; Furuse J; Geschwind JF; Ladrón de Guevara L; Papandreou C; Sanyal AJ; Takayama T; Yoon SK; Nakajima K; Cihon F; Heldner S; Marrero JA
    Int J Clin Pract; 2012 Jul; 66(7):675-83. PubMed ID: 22698419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy].
    D'Angelo S; Germano D; Zolfino T; Sansonno D; Giannitrapani L; Benedetti A; Montesarchio V; Attili A; Buonadonna A; Barni S; Gasbarrini A; Burlone ME; Cillo U; Marenco S; Villa E; Giovanis P; Proserpio I; Saitta C; Magini G; Cengarle R; Fava G; Cuttone F; Calvani N; Angelico M; Di Costanzo F; Noto A; Poggi G; Marignani M; Cascinu S; Amoroso D; Palmieri V; Massa E; Crocè LS; Picardi A; Tumulo S; Erminero C; Lencioni R; Lorusso V
    Recenti Prog Med; 2015 May; 106(5):217-26. PubMed ID: 25994538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study.
    Kudo M; Lencioni R; Marrero JA; Venook AP; Bronowicki JP; Chen XP; Dagher L; Furuse J; Geschwind JF; Ladrón de Guevara L; Papandreou C; Sanyal AJ; Takayama T; Yoon SK; Nakajima K; Lehr R; Heldner S; Ye SL
    Liver Int; 2016 Aug; 36(8):1196-205. PubMed ID: 26901163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of sorafenib in Child-Pugh A patients with unresectable hepatocellular carcinoma.
    Shen A; Tang C; Wang Y; Chen Y; Yan X; Zhang C; Liu R; Wei X; Zhu Y; Zhang H; Wu Z
    J Clin Gastroenterol; 2013; 47(10):871-80. PubMed ID: 24100749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
    Inghilesi AL; Gallori D; Antonuzzo L; Forte P; Tomcikova D; Arena U; Colagrande S; Pradella S; Fani B; Gianni E; Boni L; Laffi G; Di Costanzo F; Marra F
    World J Gastroenterol; 2014 Jan; 20(3):786-94. PubMed ID: 24574751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
    Lin SM; Lu SN; Chen PT; Jeng LB; Chen SC; Hu CT; Yang SS; Le Berre MA; Liu X; Mitchell DY; Prins K; Grevel J; Peña CA; Meinhardt G
    Hepatol Int; 2017 Mar; 11(2):199-208. PubMed ID: 27909950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
    Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
    Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib for the Treatment of Advanced Hepatocellular Cancer - a UK Audit.
    King J; Palmer DH; Johnson P; Ross P; Hubner RA; Sumpter K; Darby S; Braconi C; Iwuji C; Swinson D; Collins P; Patel K; Nobes J; Muazzam I; Blesing C; Kirkwood A; Nash S; Meyer T
    Clin Oncol (R Coll Radiol); 2017 Apr; 29(4):256-262. PubMed ID: 27964898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors.
    Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Saito T; Motoyama T; Suzuki E; Tawada A; Kanai F; Yokosuka O
    Invest New Drugs; 2015 Jun; 33(3):729-39. PubMed ID: 25861764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
    Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Tajiri N; Satani M; Niizeki T; Aino H; Okamura S; Iwamoto H; Shimose S; Shirono T; Koga H; Torimura T;
    Cancer Med; 2015 Dec; 4(12):1836-43. PubMed ID: 26471348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study.
    Daniele B; Croitoru A; Papandreou C; Bronowicki JP; Mathurin P; Serejo F; Stål P; Turnes J; Ratziu V; Bodoky G
    Future Oncol; 2015 Sep; 11(18):2553-62. PubMed ID: 26158398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.